BiomX receives positive FDA feedback for BX011 targeting S. aureus in Diabetic Foot Infections, following successful Phase 2 trial. FDA feedback on BX004 clinical hold expected soon, with enrollment and dosing ongoing outside the U.S. BiomX plans to prioritize BX011 for DFI regulatory development, with a Phase 2a trial planned. Financial results for the third quarter show cash balance at $8.1 million, sufficient to fund operations into Q1 2026. BiomX will host a conference call and webcast today at 8:30 AM ET to discuss recent updates and financial results. Research and development expenses were $6.1 million for Q3 2025, with net loss at $9.2 million.

BiomX advances clinical programs for BX004 and BX011 with FDA support. BX004 Phase 2b trial ongoing for CF patients with P. aeruginosa infections, with FDA feedback recognizing unmet needs. BX011 receives FDA positive feedback for DFI treatment, planning Phase 2a trial. Financial results show cash balance at $8.1 million, sufficient for operations into Q1 2026. Conference call and webcast today at 8:30 AM ET to discuss recent developments and financial results. Research and development expenses for Q3 2025 were $6.1 million, with net loss at $9.2 million.

Read more at GlobeNewswire: BiomX Reports Third Quarter 2025 Financial Results and